ccRCC clinical trials at UCLA
1 research study open to eligible people
Showing trials for
NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
open to eligible people ages 18 years and up
The goal of the Phase 1 portion is to identify the maximum tolerated dose (MTD) and/or the recommended doses for expansion (RDEs) of NKT2152. The Phase 2 portion will evaluate the efficacy of NKT2152 in ccRCC.
Los Angeles, California and other locations
Our lead scientists for ccRCC research studies include Brian Shuch, MD.
Last updated: